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Abstract
There is now extensive evidence that mammographic density is an
independent risk factor for breast cancer that is associated with
large relative and attributable risks for the disease. The
epidemiology of mammographic density, including the influences of
age, parity and menopause, is consistent with it being a marker of
susceptibility to breast cancer, in a manner similar to the concept
of ‘breast tissue age’ described by the Pike model. Mammographic
density reflects variations in the tissue composition of the breast. It
is associated positively with collagen and epithelial and non-
epithelial cells, and negatively with fat. Mammographic density is
influenced by some hormones and growth factors as well as by
several hormonal interventions. It is also associated with urinary
levels of a mutagen. Twin studies have shown that most of the
variation in mammographic density is accounted for by genetic
factors. The hypothesis that we have developed from these
observations postulates that the combined effects of cell
proliferation (mitogenesis) and genetic damage to proliferating
cells by mutagens (mutagenesis) may underlie the increased risk
for breast cancer associated with extensive mammographic
density. There is clearly a need for improved understanding of the
specific factors that are involved in these processes and of the role
played by the several breast tissue components that contribute to
density. In particular, identification of the genes that are
responsible for most of the variance in percentage density (and of
their biological functions) is likely to provide insights into the
biology of the breast, and may identify potential targets for
preventative strategies in breast cancer.
Introduction
Following Wolfe’s original studies [1,2], the proportion of the
breast area in the mammogram that is occupied by
radiologically dense breast tissue (mammographic density) is
now recognized to be a strong risk factor for breast cancer
that may account for a large fraction of the disease [3,4] (see
the review by Vachon and coworkers in this series [5]). In the
present paper we review what is known of the aetiology of
mammographic density and outline hypotheses for its
association with risk for breast cancer.
We describe below the evidence that mammographic density
is a marker of susceptibility to breast cancer, and we review
what is known of the histology of radiologically dense breast
tissue, and the influence of other risk factors for breast cancer.
We describe associations of hormones, growth factors and a
mutagen with mammographic density, and the evidence that
mammographic density is influenced by genetic variants.
We propose that cumulative exposure to mammographic
density may be an important determinant of breast cancer
incidence, and that the risk for breast cancer associated with
mammographic density may be explained by the combined
effects of mitogens, which influence cell proliferation and the
size of the cell population in the breast, and mutagens, which
influence the likelihood of genetic damage to those cells.
Figure 1 panels a and b, respectively, provide a schematic
overview and a more detailed description of aspects of these
hypotheses that are examined in the sections that follow. The
available evidence is incomplete in many of these areas,
however. In addition, all studies of the aetiology of mammo-
graphic density are constrained by the limitations of current
methods of measuring density (see the review by Yaffe and
coworkers in this series [5]).
Ultimately, the risk for breast cancer associated with
mammographic density will be elucidated by an improved
understanding of the biology of the breast (see the review by
Tisty and coworkers in this series [5]). However, just as
epidemiological methods have identified mammographic
density as an important risk factor for breast cancer, whose
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biology is likely to play an important role in the aetiology of the
disease, epidemiological approaches may be able to suggest
potential pathways and mechanisms that are responsible for
risk.
Cumulative exposure to mammographic
density and breast cancer incidence
The average percentage mammographic density declines
with increasing age (Figure 2a), whereas breast cancer
Figure 1
Hypotheses. (a) Schematic summary. We postulate that the combined effects of cell proliferation (mitogenesis) and genetic damage to
proliferating cells caused by mutagens (mutagenesis) may underlie the increased risk for breast cancer associated with extensive mammographic
density. Mitogenesis and mutagenesis are related processes. Increased cell proliferation increases susceptibility to mutations but also increases
lipid peroxidation, which can in turn increase cell proliferation (see text). (b) Biological hypothesis. The tissue components (epithelial cells, stromal
cells, collagen and fat) that are responsible for variations in mammographic density are related to each other in several ways. Stromal fibroblasts
produce collagen, and some are pre-adiopocytes that differentiate into adipocytes. Stromal and epithelial cells influence each other through
paracrine growth factors, and both cell types are influenced by endocrine stimuli to cell proliferation (mitogenesis). Genetic damage to either
stromal or epithelial cells caused by mutagens (mutagenesis) could initiate carcinogenesis (see text).Page 3 of 14
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incidence increases with age (Figure 2b [left]). This apparent
paradox may be resolved, however, by reference to a model
of breast cancer incidence proposed by Pike and coworkers
[6]. This model is based on the concept that it is the rate of
breast tissue ‘ageing’ or ‘exposure’, rather than chronological
age, that is the relevant measure for describing the age-
specific incidence of breast cancer (Figure 2b [right]). Breast
tissue ageing is thought to be closely related to the mitotic
activity of breast epithelial or stem cells and their
susceptibility to genetic damage. According to the model,
shown in Figure 2b (right), the rate of breast tissue ageing is
most rapid at the time of menarche, slows with pregnancy,
Available online http://breast-cancer-research.com/content/10/1/201
Figure 2
Age, mammographic density and the incidence of breast cancer. (a) Baseline percentage mammographic density in women from three
mammographic screening programmes according to those who developed breast cancer 1 to 8 years later (cases) or remained free from breast
cancer (control individuals). Average percentage density in the baseline mammogram declined with increasing age at enrolment, both in women
who eventually developed breast cancer and in those who remained free from disease. At all ages, percentage density was greater in those who
developed breast cancer. Data from Boyd and coworkers [4]. (b) On the left is shown a log-log plot of the age-specific incidence of breast cancer.
Adapted from Pike and coworkers [6]. To the right is shown the Pike model of breast tissue ageing. ‘b’ represents a one time increase in risk
associated with first full-term pregnancy (FFTP). See Pike and coworkers [6]. LMP, last menstrual period.slows further during the peri-menopausal period, and is least
after the menopause. After fitting numeric values for these
parameters, Pike and coworkers [6] showed that cumulative
exposure to breast tissue ageing, given by the area under the
curve in Figure 2b (right), described the age-incidence curve
for breast cancer in the USA, also shown in Figure 2b (left).
Thus, cumulative exposure to breast tissue ageing and the
age-specific breast cancer incidence both increase with age,
but the rate of increase slows with age, particularly after
menopause.
Mammographic density shares many of the features of ‘breast
tissue age’ and is influenced by similar factors. Detailed
descriptions of the associations of risk factors with mammo-
graphic density can be found elsewhere [7-9]. Body size in
particular is strongly and inversely associated with mammo-
graphic density, and is a risk factor for breast cancer
independent of mammographic density [10]. We focus here
on the associations of mammographic density with age, parity
and menopause, variables in the Pike model that are also
associated with variations in one or more of the histological
features of the breast [11].
In addition to the effects of age referred to above,
mammographic density is less extensive in women who are
parous and in those with a larger number of live births
(Figure 3). In these data each pregnancy was associated with
an average 2% difference in percentage density [4]. Post-
menopausal women have consistently been found to have
less extensive mammographic density than premenopausal
women, and a longitudinal study of the effects of the
menopause on mammographic density [12] showed that
percentage density was reduced by about 8% on average
over the menopause.
All risk factors for breast cancer must ultimately exert their
influence by an effect on the breast. These findings suggest
that, for at least some risk factors, this influence includes an
effect on the number of cells and the quantity of collagen in
the breast, which is reflected in differences in mammographic
density and which may mediate the effect of the factor on
breast cancer risk (see ‘Breast histology and radiological
features’, below). The concept of breast tissue age in the
Pike model is related to the effects of hormones on the
kinetics of breast cells and the accumulation of genetic
damage. As we discuss below, mammographic density may
reflect cumulative exposure to stimuli to division of breast
cells that predisposes them to genetic damage by mutagens.
In addition to the cross-sectional data shown in Figure 2a,
longitudinal studies [13,14] have found that percentage
mammographic density in women who develop breast cancer
was greater than in those who remained free from disease,
but neither study showed that the rate of change over time
was related to breast cancer risk. Both studies were based
primarily on postmenopausal women, and it remains possible
that differences in rate of change in mammographic density
earlier in life may be related to later risk for breast cancer.
Breast histology and radiological features
Breast histology and mammographic density
Studies of the relationship between breast tissue histology
and the radiological appearance of the breast (described in
detail by Boyd and coworkers [9]), using surgical biopsies or
mastectomy specimens, have found greater amounts of
epithelium and/or stroma to be associated with mammo-
graphic density.
Li and coworkers used quantitative microscopy to examine
histological features of randomly selected tissue blocks from
breast tissue obtained at forensic autopsy [15,16] and
determined the proportions of the biopsy occupied by cells
(estimated by nuclear areas), glandular structures and collagen
[11]. Figure 4 from that study [11] shows the inverse
association of percentage density (in the image of the breast
tissue slice from which the biopsy was taken) with age, and
associations of percentage density with measured components
of breast tissue, expressed as a percentage of the total area of
the section. Greater percentage mammographic density was
associated with a significantly greater total nuclear area, a
greater nuclear area of both epithelial and nonepithelial cells, a
greater proportion of collagen, and a greater area of glandular
structures. Of the tissue components measured, collagen was
present in the greatest quantity, was most strongly associated
with percentage density, and explained 29% of the variance in
percentage density. Nuclear area and glandular area accounted
for between 4% and 7% of the variance in percentage density.
Breast Cancer Research    Vol 10 No 1 Martin and Boyd
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Figure 3
Parity and mammographic density. Least square means of percentage
mammographic density according to number of live births, adjusted for
age, body mass index, age at menarche, age at first birth, menopausal
status, age at menopause, previous use of menopausal hormone
therapy (ever/never) and breast cancer in first degree relatives (0, 1,
2+). The height of the bar is the least square mean of percentage
density, and half width of the error bar represents the standard error.
Data from Boyd and coworkers [4].Greater body weight, parity and greater number of births, and
postmenopausal status were associated with quantitative
differences in one or more of the tissue features measured in
the autopsy samples described above (see Li and coworkers
[11] for details). For example, greater body weight and
postmenopausal status were inversely associated with all of
the histological measures, and the percentage of collagen in
the biopsy declined with parity and increasing number of live
births. Each live birth was associated with an average
reduction by 2% [11]. These factors were all associated with
variations in mammographic density in this [11] and other
studies [8,9], and with risk for breast cancer [17].
Breast histology and risk of breast cancer
Extensive mammographic density is associated with an
increased risk for atypical hyperplasia and in situ breast
cancer [18], which are associated with an increased risk for
subsequent invasive breast cancer [19,20]. The reductions in
collagen and glandular tissue, and the increase in fat that
occur in the breast with increasing age have long been
recognized by pathologists as ‘involution’, and Milanese and
coworkers [21] demonstrated, using a definition that focused
the degree of involution in the terminal duct lobular unit, that
greater involution was associated with a reduced risk for
breast cancer. The reduction in mammographic density with
age is associated with smaller proportions of collagen and
glandular tissue in the breast [11] and may be related to
involution of the terminal duct lobular unit.
Relationships among histological structures that are
responsible for density
Epithelial and stromal cells, collagen and fat - the tissue
components that contribute to mammographic density - are
related to each other in several ways that are illustrated in
Figure 1b. Epithelial and stromal cells communicate by means
of paracrine growth factors (see the review by Tisty and
coworkers in this series [5]). Collagen is a product of stromal
fibroblasts, and adipocytes develop from stromal pre-
adipocytes [22]. Factors that affect one of these components
may therefore affect the others, directly or indirectly, and each
component has properties that may influence risk for and
progression of breast cancer.
Breast cancer arises from epithelial cells, and the number and
proliferative state of these cells may influence both the
radiological density of the breast and the probability of
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Figure 4
Percentage mammographic density, age, and histological measures. Boxplots showing the associations of percentage density with age and
histological measures. Median is shown by a horizontal line, mean by the ‘+’ symbol, interquartile range by the columns, 1.5× the interquartile range
by the whiskers, and outliers are shown separately. P values from linear regression, using continuous variables adjusted for age, were as follows:
age, P = 0.04; total nuclear area, P < 0.001; epithelial nuclear area, P ≤ 0.001; nonepithelial nuclear area, P < 0.001; collagen, P < 0.001;
glandular area, P < 0.001. Data from Li and coworkers [11].genetic damage that may give rise to cancer. In addition,
collagen and stromal matrix are products of stromal cells that
may, through their mechanical properties, facilitate tumour
invasion [23]. Metalloproteinases that regulate stromal matrix
can also regulate the activation of growth factors and
influence susceptibility to breast cancer [24,25].
Mitogenesis
Mitogens as potential mediators of effects: hormones
and growth factors.
As shown in Figure 1a,b, the effects of age and other factors
on breast tissue composition that are described above (and
further below) are likely to be mediated at least in part by one
or more of the several endocrine, paracrine and autocrine
mechanisms that regulate the growth and development of
breast stroma and epithelium. Variations in exposure or
response to one or more of these mechanisms may explain
the effects that genetic and environmental factors have on
differences in breast tissue composition. Most studies to date
have focused on endocrine influences.
Blood levels of hormones and growth factors
The results of cross-sectional studies that have examined
blood levels of steroid sex hormones and growth factors in
relation to mammographic density are summarized in Tables 1
and 2. The studies vary in design, size, method of sampling
patients, methods of measuring density, and methods of
analysis. All have assessed the association between the
blood and mammographic measures after adjustment for
other factors that are known to influence density.
Most studies of blood oestrogen levels and percentage
mammographic density have found either no association or
an inverse association with estrone levels (five out of seven
studies) [26-30] or total or free estradiol (seven out of eight
studies) [26-32] in premenopausal or postmenopausal women.
An exception is the study carried out in the Postmenopausal
Estrogen/Progestin Intervention Trial [33], which identified a
positive association between percentage density and
estrone, estradiol and free estradiol levels in postmenopausal
women. Bremnes and coworkers [32] found a positive
association of mammographic density with estrone levels
(which was statistically significant only in women with insulin-
like growth factor [IGF]-I levels below the median) but not
with estradiol or free estradiol levels. Progesterone levels
have not been shown to be associated with mammographic
density in premenopausal or postmenopausal women. Sex
hormone binding globulin has been found to have a
significant positive association with mammographic density in
two studies after adjustment for other variables [31,32], and
in four other studies before adjustment [26,27,30,33].
Testosterone and androstenedione have not been shown to
be associated with mammographic density in post-
menopausal women and have not yet been studied in
premenopausal women.
Blood levels of growth hormone have been found to be
positively associated with mammographic density in pre-
menopausal women, but this association became non-
significant after adjustment for body size [31]. Because
growth hormone is one of the factors that influences body
size, this may be over-adjustment. Prolactin levels were found
to be positively associated with the area of dense tissue in
premenopausal women in one study [31], with percentage
mammographic density in postmenopausal women in two
studies [31,34], and in a further study statistical significance
was lost after adjustment for other variables [27]. Mammo-
graphic density was found to be positively associated with
serum IGF-I levels in premenopausal women in three
[31,35,36] out of five studies [37,38], and one study found
an association in postmenopausal women [39]. Results with
IGF-binding protein (IGFBP)-3 and the ratio of IGF-I to
IGFBP-3 have been inconsistent. In a longitudinal study,
women with higher levels of serum IGF-I during the pre-
menopausal period experienced a smaller increase nondense
area and a slightly smaller decrease in dense area during
menopause [40].
Growth factors in breast tissue
To date, few studies have examined growth factors or stromal
matrix proteins in breast tissue in relation to mammographic
density. One study [41] was conducted in formalin-fixed
paraffin blocks of breast tissue (n = 92) surrounding benign
lesions, half from breasts with little or no radiological density
and half from breasts with extensive density, and included
groups matched for age at the time of biopsy. Similar to the
results of the study conducted by Li and coworkers [11]
described above, breast tissue from women with extensive
densities had a greater nuclear area and a larger stained area
of collagen. In addition, stained areas of immunohisto-
chemistry for tissue inhibitor of matrix metalloproteinase-3
and IGF-I were greater in women with extensive density than
in those with little breast density [41]. Stromal proteoglycans
that are expressed in association with breast cancer have
also been found to be associated with mammographic
density [42].
Breast tissue response to hormones
Combined estrogen-progesterone menopausal hormone
therapy, but not estrogen therapy alone, is associated with a
small increase in risk for breast cancer [43], and increases
mammographic density [44-46]. Percentage density is
reduced by tamoxifen [47], and by a gonadotrophin-releasing
hormone agonist [48] that reduces exposure to estrogen and
progesterone in premenopausal women. The average reduc-
tions in percentage density associated with these hormonal
interventions are modest, in general less than 10%.
Hormones and growth factors: risk factors and risk for
breast cancer
Estradiol and testosterone blood levels have been shown to
be related to risk for breast cancer in premenopausal and
Breast Cancer Research    Vol 10 No 1 Martin and Boyd
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have not consistently been shown to be associated with
mammographic density, suggesting that they may influence
risk through pathways that are unrelated to density. In
support of this idea, Tamimi and coworkers [51] recently
reported that circulating sex steroid levels and mammo-
graphic density are independently associated with breast
cancer risk in postmenopausal women. However, it remains
possible that other forms of estrogen not measured in these
studies, including estrogen metabolites, may influence
mammographic density [52] and the associated risk for
breast cancer [53]. Estrogens can induce lipid peroxidation
(see below) [54], and catechol estrogens (metabolites of
estrone and estradiol) can react with DNA to form adducts
[55] that may initiate cancer.
Blood levels of IGF-I and prolactin have also been found to
be associated with risk for breast cancer, IGF-I predominantly
in premenopausal women, and prolactin in both premeno-
pausal and postmenopausal women [56,57]. IGF-I is a known
mitogen for breast epithelium that is produced in the breast
stroma, as well as by the liver in response to growth hormone
[58], and administration of growth hormone to ageing
primates has been shown to induce epithelial proliferation
[59]. Prolactin increases cell proliferation and decreases
apoptosis in the breast, and higher blood levels have been
found to be associated with an increased risk for breast
cancer in both premenopausal and postmenopausal women
[60]. Prolactin plays an important role in the development and
progression of mammary tumours in rodents [61].
Mammographic density, IGF-I and prolactin levels are all
Available online http://breast-cancer-research.com/content/10/1/201
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Table 1
Studies of steroid sex hormones, SHBG, and mammographic density 
Direction of association [ref.]
Number of  Menopausal 
Hormone studiesa status Positive None Inverse
Estrone 7 Premenopausal Noh  et al. [26]
Postmenopausal Bremnes et al. [32],  Tamimi et al. [27]2, Aiello et al. [28]b, Aiello  et al. [28]c
Greendale et al. [33] Warren et al. [29], Verheus et al. [30]2
Estradiol 8 Premenopausal Noh et al. [26]1, Boyd et al. [31]
Postmenopausal Greendale et al. [33] Tamimi et al. [27]2, Aiello et al. [28]b, Aiello  et al. [28]c
Warren et al. [29], Verheus et al. [30]2, 
Boyd et al. [31], Bremnes et al. [32]
Free estradiol 8 Premenopausal Noh et al. [26], Boyd et al. [31]
Postmenopausal Greendale et al. [33] Tamimi et al. [27]2, Aiello et al. [28]b, Aiello  et al. [28]c, 
Warren et al. [29], Verheus et al. [30]2, Boyd  et al. [31]
Bremnes et al. [32]
Progesterone 5 Premenopausal Noh et al. [26]1, Boyd et al. [31]1
Postmenopausal Tamimi et al. [27], Warren et al. [29], 
Boyd et al. [31], Greendale et al. [33]
SHBG 8 Premenopausal Noh et al. [26]1, Boyd et al. [31]1
Postmenopausal Boyd et al. [31],  Tamimi et al. [27]1, Aiello et al. [28]b,c, 
Bremnes et al. [32] Warren et al. [29], Verheus et al. [30]1, 
Greendale et al. [33]1
Testosterone 6 Premenopausal NA
Postmenopausal Tamimi et al. [27], Aiello et al. [28]b, Aiello  et al. [28]c
Warren et al. [29], Verheus et al. [30]2, 
Bremnes et al. [32], Greendale et al. [33]
Androstenedione 5 Premenopausal NA
Postmenopausal Tamimi et al. [27], Aiello et al. [28]b, Aiello  et al. [37]c
Warren et al. [29], Verheus et al. [30], 
Bremnes et al. [32]
Associations shown are for percentage density. Associations were classified as positive, none, or inverse according to the direction of effect and
the statistical significance of the values after adjustment for other factors, using a criterion of P < 0.05. Several associations were statistically
significant before adjustment for other factors and these are indicated as follows: 1positive association before adjustment and 2inverse association
before adjustment. aSome studies included both premenopausal and postmenopausal women. bResults for never users of hormones. cResults for
users of hormones. SHBG, sex hormone binding globulin; NA, not assessed.influenced by age, parity and number of births in a similar
manner [62,63].
Mutagenesis
Mutagens as potential mediators of effects: oxidative
stress
Oxidative stress occurs when an excess of reactive oxygen
species (ROS) is produced in relation to antioxidant defences
and can cause oxidative damage to DNA, protein and lipid
molecules. DNA damage can lead to mutagenesis and
increased risk for cancer [64]. Inflammation is also
associated with increased ROS and may be an additional
pathway that relates oxidative stress to cancer risk [65].
A variety of biomarkers for measurement of oxidative stress in
vivo have been proposed, including markers of oxidative
damage to DNA, protein and lipids [66], but a recent
validation study in rats indicated that blood or urinary isopros-
tanes and urinary malondialdehyde (MDA) are the best
indicators of in vivo oxidative stress [67]. These compounds
are products of lipid peroxidation produced from the free
radical mediated oxidation of arachidonic acid. Isoprostane is
a prostaglandin-like compound [68] and MDA is a known
mutagen [69,70].
Urinary malondialdehyde and mammographic density
A positive association between mammographic density and
24-hour urinary MDA excretion was observed in three
independent studies [71-73]. In premenopausal and post-
menopausal women, representing a wide range of
mammographic density [72,73], urinary MDA excretion was
23% to 30% higher in the highest quintile of mammographic
density as compared with the lowest, after adjustment for age
and body mass index or waist circumference (Table 3).
Measures of body size, which are negatively associated with
mammographic density and positively associated with
oxidative stress, are important potential confounders of the
relationship between urinary MDA and percentage mammo-
Breast Cancer Research    Vol 10 No 1 Martin and Boyd
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Table 2
Studies of pituitary hormones, related growth factors, and mammographic density
Direction of association [ref.]
Number of  Menopausal 
Hormone studiesa status Positive None Inverse
Growth hormone 1 Premenopausal Boyd et al. [31]1
Postmenopausal Boyd et al. [31]1
Prolactin 4 Premenopausal Boyd et al. [31] 
(dense area only)
Postmenopausal Boyd et al. [31],  Tamimi et al. [27]1, Bremnes et al. [39]
Greendale et al. [34]
IGF-I 7 Premenopausal Boyd et al. [31],  Maskarinec et al. [37], 
Byrne et al. [35],  dos Santo Silva et al. [38]
Diorio et al. [36]
Postmenopausal Bremnes et al. [39] Aiello et al. [28]b,c, Boyd et al. [31], 
Byrne et al. [35], Diorio et al. [36]1, 
dos Santo Silva et al. [38]
IGFBP-3 7 Premenopausal Boyd et al. [31], Byrne et al. [35],  Diorio et al. [36]
Maskarinec et al. [37], 
dos Santos Silva et al. [38]
Postmenopausal Aiello et al. [28]b,c, Boyd et al. [31], 
Byrne et al. [35], dos Santos Silva 
et al. [38]2, Bremnes et al. [39]
IGF-I/IGFBP-3 ratio 7 Premenopausal Boyd et al. [31],  Diorio et al. [36]1, 
Byrne et al. [35],  dos Santos Silva et al. [38]
Maskarinec et al. [37]
Postmenopausal Bremnes et al. [39] Aiello et al. [28]b, Boyd et al. [31],  Aiello et al. [28]c
Byrne et al. [35], Diorio et al. [36]1, 
dos Santos Silva et al. [38]
Associations shown are for percentage density, unless otherwise indicated. Associations were classified as positive, none, or inverse according to
the direction of effect and the statistical significance of the values after adjustment for other factors, using a criterion of P < 0.05. Several
associations were statistically significant before adjustment for other factors and these are indicated as follows: 1positive association before
adjustment and 2inverse association before adjustment. aSome studies included both premenopausal and postmenopausal women. bResults for
never users of hormones. cResults for users of hormones. IGF, insulin-like growth factor; IGFBP, insulin-like growth factor binding protein.graphic density. This relationship becomes stronger [71], or
is only evident [72,73], after adjustment for body size. Serum
levels of MDA and MDA DNA adducts were not associated
with mammographic density [73].
It is unknown whether systemic levels of lipid peroxidation
markers, such as urinary MDA, reflect breast tissue levels.
However, women with breast cancer who received radiation
to the breast (which induces oxidative stress and inflam-
mation) exhibited significantly increased urinary excretion of
isoprostanes as compared with those women with breast
cancer who did not receive such treatment [74].
Oxidative stress: risk factors and risk of breast cancer
The protective effects of higher fruit and vegetable intake and
serum antioxidant levels on breast cancer risk seen in some
studies, and studies showing that genetic polymorphisms in
some antioxidant enzymes are associated with breast cancer
risk provide indirect evidence for a role of oxidative stress in
the development of breast cancer [75,76]. Direct evidence of
an association of oxidative stress with breast cancer risk
arises from case control studies of patients with and without
breast cancer. Plasma MDA was elevated in breast cancer
patients relative to levels in healthy control individuals
[77-79]. Levels of MDA DNA adducts and 8-hydroxy-2-deoxy-
guannosine (markers of DNA damage) were significantly
higher in normal breast tissue of cancer patients than in the
breast tissue of control individuals without cancer [80-82].
Recently, a large case control study identified a significant
trend toward increasing breast cancer risk with increasing
urinary excretion of isoprostanes [74]. A limitation of the
studies cited above is that the markers of oxidative stress
were measured in biological samples collected after breast
cancer diagnosis, and therefore the higher levels of oxidative
stress in cases could be due to the presence of cancer or its
treatment.
Several lines of evidence suggest that there is an association
between oxidative stress and some factors that are known or
suspected to influence risk for breast cancer. Chinese
women living in China have lower levels of urinary MDA
excretion [83] and lower breast cancer risk than do Chinese
women living the USA, and Chinese American women have
lower urinary isoprostane excretion than Caucasian American
women [84]. The lower risk and oxidative stress observed in
Asian women may be related to their lower body weight and
dietary fat intake compared with Caucasian women. Lower
body weight is associated with lower breast cancer risk [85]
and lower levels of isoprostane [86,87]. Lower dietary fat
intake may be associated with reduced breast cancer risk
[88] and with reduced oxidative stress [84,89]. Chronic
moderate levels of activity increase antioxidant activity
[90,91] and are associated with reduced breast cancer risk
[92]. However, the role that these factors play in risk for
breast cancer associated with mammographic density is not
yet clear. For example, Asian women tend to have greater
percentage density than do Caucasian women (probably as a
result of smaller breast size) [93], the effect of body weight
on breast cancer is probably independent of mammographic
density [10], and physical activity does not appear to be
associated with mammographic density [94,95].
In terms of reproductive risk factors known to be associated
with mammographic density, markers of oxidative stress are
higher in postmenopausal than in premenopausal women
[73,96] and may be reduced by menopausal hormone
therapy [97] and tamoxifen [98]. However, estrogen and its
metabolites have both anti-oxidant and pro-oxidant effects
[99], and urinary isoprostane excretion was not associated
with blood estrogen levels [100]. Higher alcohol intake is
associated with higher breast cancer risk [101], plasma
isoprostane levels [102], and mammographic density
[72,103].
Relationship of mitogenesis and mutagenesis
Increased cell proliferation can cause an increase in
production of ROS and lipid peroxidation, and the products
of lipid peroxidation themselves can promote cell proliferation
via cell signalling [104] (Figure 1a). Interestingly, MDA and
isoprostanes (products of lipid peroxidation) have been
reported to be mediators of the increased cell proliferation
and collagen production seen in hepatic fibrosis [105].
Fibrosis, a response to tissue injury and inflammation (which
increase oxidative stress), involves the proliferation and
Available online http://breast-cancer-research.com/content/10/1/201
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Table 3
Urinary excretion of MDA by quintile of percentage mammographic density
Quintiles of percentage density
12 34 5 P value for trend
Premenopausal (n = 160) 2.76a 2.29 2.86 2.75 3.62 0.02
Postmenopausal (n = 175) 3.19 3.23 3.67 3.46 3.88 0.13
All women (n = 335) 3.02 2.76 3.10 3.38 3.68 0.01
Values for malondialdehyde (MDA) are expressed as mmol/day. For ‘All women’, values are also adjusted for menopausal status. aLeast square
mean of MDA adjusted for age and waist circumference (negative inverse). Data are from Hong and coworkers [73].activation of fibroblasts and results in accumulation of extra-
cellular matrix and collagen [106]. It is unknown whether the
process of fibrosis is related to mammographic density and
increased risk for breast cancer. However, chronic inflam-
mation and/or the wound healing response may be involved
in the initiation or promotion of cancer [24,107], and the
presence of breast cancer is associated with reactive stroma,
a process that resembles fibrosis [108] that is thought to
promote tumour progression and invasion. Thus, the associa-
tion of increased MDA with higher mammographic density
may be either a cause or an effect of increased cell
proliferation and collagen production, and the risk for breast
cancer may be increased by these processes as well as by
mutagenesis. As shown in the Figure 1b both stromal and
epithelial cells are potential sites of mutagenesis, either of
which might initiate processes that ultimately give rise to
breast cancer.
Heritability of mammographic density
Parity, menopause and other risk factors explain only 20% to
30% of the variance in mammographic density [8,109]. Early
studies of mother-daughter sets [110,111] and small twin
studies [111,112] suggested that genetic factors might
explain a proportion of the variation (the heritability) of breast
tissue patterns within a given population. A segregation
analysis of nuclear family data conducted Pankow and co-
workers [113] yielded findings consistent with a single mode
of inheritance of one or more major genes, but it could not
distinguish  between dominant, recessive, or co-dominant
models.
Twin studies conducted in Australia and North America
identified correlations between twin pairs in percentage
mammographic density that were, respectively, 0.61 and
0.67 for monozygotic twin pairs, and 0.25 and 0.27 for
dizygotic twin pairs [114]. After adjustment for the other risk
factors associated with differences in mammographic density,
the proportion of the residual variation accounted for by
additive genetic factors (heritability) was 63% (95%
confidence interval 59% to 67%) in the studies combined,
and was similar in each of the two studies. These two twin
studies thus replicate each other in providing compelling
evidence that the wide variation in percentage
mammographic density among women is strongly influenced
by genetic factors.
The search for genes associated with mammographic density
is in its infancy and few have been found to date. Several
large-scale genome-wide linkage and association studies are
in progress and can be expected to report their findings
within the next few years. The preliminary results from one
genome-wide sib-pair linkage study [115] provide evidence
for linkage at a region on chromosome 6. Vachon and
coworkers [116] recently reported results of a genome-wide
linkage scan that showed that a putative locus on
chromosome 5p may account for a large proportion of the
variance in mammographic density. Among association
studies conducted to date, variations in genes concerned
with estrogen metabolism [117-120], the estrogen [121] and
androgen [122] receptors, IGFBP-3 [123], IGF [124] and
growth hormone [125] have been shown to be associated
with mammographic density. To date, few of these findings
have been replicated, and some that have been replicated
[117,118] have also been contradicted [119,120].
Among potential genetic influences suggested by our
hypothesis shown in Figure 1a,b are effects on the produc-
tion and metabolism of breast mitogens [126], effects on the
change in mitogens that occurs with ageing [127], the
response of stromal and epithelial breast tissue to stimulation
by mitogens [128], and tissue modelling in the breast [129].
The production and metabolism of mutagens may also be
under genetic control [130], as is the repair of DNA damage
caused by mutagens [131]. Some factors already found to be
associated with mammographic density are also involved in
processes that generate mutagens or modify their effects.
These include catechol-O-methyltransferase, which is
involved in the metabolism of catechol estrogens with pro-
oxidant and anti-oxidant activities [117], and cytochrome
P450 1A2 [73], which has been found to be associated with
serum and urinary MDA levels. These associations require
confirmation, however.
Summary
There is now extensive evidence that mammographic density
is a risk factor for breast cancer, independent of other risk
factors, and is associated with large relative and attributable
risks for the disease. The hypotheses that we have developed
from the observations described above are summarized here
and illustrated in Figure 1a,b.
Cumulative exposure to mammographic density and
breast cancer risk
Mammographic density reflects variations in the tissue
composition of the breast, and is associated positively with
collagen and epithelial and nonepithelial cells, and negatively
with fat. Increasing age, parity, and menopause are all
associated with reductions in the epithelial and stromal
tissues in the breast, and with an increase in fat. These
histological changes are reflected in the radiological
appearance of the breast, and are consistent with mammo-
graphic density being a marker of susceptibility to breast
cancer, in a manner similar to the concept of ‘breast tissue
age’ described in the Pike model [6,132]. Like breast tissue
age, variations in mammographic density may reflect the
mitotic activity of breast cells and differences in susceptibility
to genetic damage, and cumulative exposure to density may
have an important influence on breast cancer incidence.
Mitogens, mutagens and mammographic density
Mammographic density is influenced by some hormones and
growth factors, as well as by several hormonal interventions,
Breast Cancer Research    Vol 10 No 1 Martin and Boyd
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postulate that the combined effects of cell proliferation
(mitogenesis) and genetic damage to proliferating cells by
mutagens (mutagenesis) may underlie the increased risk for
breast cancer associated with extensive mammographic
density. As described above under ‘Relationship of mito-
genesis and mutagenesis’, mitogenesis and mutagenesis are
not independent processes. Increased cell proliferation can
increase lipid peroxidation, and the products of lipid
peroxidation can increase cell proliferation.
Blood levels of IGF-I and prolactin are among the endocrine
stimuli to cell proliferation that have been found to be
positively associated with both mammographic density and
breast cancer risk, respectively, in premenopausal and post-
menopausal women [56,57].
Autocrine and paracrine stimuli to the proliferation of
epithelial and stromal cells, which regulate the growth,
development and involution of the breast [25,133], have to
date received little attention in relation to mammographic
density, but one study [41] has identified an association of
density with IGF-I in breast tissue. Animal models have shown
that growth factors from fibroblasts can stimulate or inhibit
epithelial proliferation, and that the genetic modification of
fibroblasts can induce cancer [24,25,133].
The proliferation of cells that results from stimulation by
endocrine, autocrine and paracrine growth factors increases
risk for mutation [134]. To date the association of only one
mutagen has been examined in relation to mammographic
density, but greater levels of urinary excretion of MDA (a
mutagenic product of lipid peroxidation) was found in three
independent studies to be associated with more extensive
mammographic density.
Potential areas for genetic influence include variation in the
regulation of the hormones and growth factors that act on the
breast, the response and modelling of breast tissue to these
stimuli, and the processes that are involved in oxidative stress
and the generation of mutagens.
Conclusion
Although there is evidence that both mitogenic and
mutagenic processes are involved in determining the risk for
breast cancer associated with mammographic density, there
is clearly a need for an improved understanding of the
specific factors involved and of the role played by the several
breast tissue components that contribute to density. In
particular, the identification of the genes that are responsible
for most of the variance in percentage density (and of their
biological functions) is likely to provide insights into the
biology of the breast and may identify potential targets for
preventative strategies for breast cancer.
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